Immunotherapy found efficacious as second-line therapy – ModernMedicine
|
Immunotherapy found efficacious as second-line therapy
ModernMedicine Results of KEYNOTE-045, an international randomized phase III study, show that pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma (UC) provided superior overall survival and a better safety profile compared with commonly … |
